Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis

American Heart Journal

Volumn 184, Issue , 2017, Pages 37-46

  Van Der Meersch, Hans ^a   De Bacquer, Dirk ^b   De Vriese, An S ^a  

^a AZ Sint Jan Brugge   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; ANTICOAGULANT AGENT; VITAMIN K GROUP; WARFARIN;

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHADS2 SCORE; CHRONIC KIDNEY DISEASE; HEMODIALYSIS PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY GRAFT; META ANALYSIS; MORTALITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CAUSE OF DEATH; CHEMICALLY INDUCED; COMPLICATION; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; PROPORTIONAL HAZARDS MODEL; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CAUSE OF DEATH; CEREBRAL HEMORRHAGE; HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; MORTALITY; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; STROKE; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84995751278     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.09.016     Document Type: Article

References (41)

1. 1. Zimmerman, D., Sood, M.M., Rigatto, C., et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 27:10 (2012), 3816–3822.
2. 2. Freedman, B., Potpara, T.S., Lip, G.Y., Stroke prevention in atrial fibrillation. Lancet 388:10046 (2016), 806–817.
3. 3. Providência, R., Marijon, E., Boveda, S., et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol 114:4 (2014), 646–653.
4. 4. De Vriese, A.S., Caluwé, R., Raggi, P., The atrial fibrillation conundrum in dialysis patients. Am Heart J 174 (2016), 111–119.
5. 5. Herrington, W., Haynes, R., Staplin, N., et al. Evidence for the prevention and treatment of stroke in dialysis patients. Semin Dial 28:1 (2015), 35–47.
6. 6. Sood, M.M., Larkina, M., Thumma, J.R., et al. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. Kidney Int 84:3 (2013), 600–608.
7. 7. Caluwé, R., Pyfferoen, L., De Boeck, K., et al. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Clin Kidney J 9:2 (2016), 273–279.
8. 8. Wizemann, V., Tong, L., Satayathum, S., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77:12 (2010), 1098–1106.
9. 9. Juma, S., Thomson, B.K., Lok, C.E., et al. Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty. BMC Nephrol, 14, 2013, 174.
10. 10. Phelan, P.J., O'Kelly, P., Holian, J., et al. Warfarin use in hemodialysis patients: what is the risk?. Clin Nephrol 75:3 (2011), 204–211.
11. 11. Hayashi, M., Abe, T., Iwai, M., et al. Safety of warfarin therapy in chronic hemodialysis patients: a prospective cohort study. Clin Exp Nephrol 20:5 (2016), 787–794.
12. 12. Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:4 (2009), 264–269 [W64].
13. 13. Bonde, A.N., Lip, G.Y., Kamper, A.L., et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 64:23 (2014), 2471–2482.
14. 14. Shah, M., Avgil Tsadok, M., Jackevicius, C.A., et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 129:11 (2014), 1196–1203.
15. 15. Lai, H.M., Aronow, W.S., Kalen, P., et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis 2 (2009), 33–37.
16. 16. Wang, T.K., Sathananthan, J., Marshall, M., et al. Relationships between anticoagulation, risk scores and adverse outcomes in dialysis patients with atrial fibrillation. Heart Lung Circ 25:3 (2016), 243–249.
17. 17. Friberg, L., Benson, L., Lip, G.Y., Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 36:5 (2015), 297–306.
18. 18. Carrero, J.J., Evans, M., Szummer, K., et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 311:9 (2014), 919–928.
19. 19. Chen, J.J., Lin, L.Y., Yang, Y.H., et al. Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atril fibrillation—a nation-wide database analyses. Int J Cardiol 177:3 (2014), 1008–1011.
20. 20. Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:9 (2011), 603–605.
21. 21. Olesen, J.B., Lip, G.Y., Kamper, A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:7 (2012), 625–635.
22. 22. Chan, K.E., Lazarus, J.M., Thadhani, R., et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20:10 (2009), 2223–2233.
23. 23. Winkelmayer, W.C., Liu, J., Setoguchi, S., et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 6:11 (2011), 2662–2668.
24. 24. Wakasugi, M., Kazama, J.J., Tokumoto, A., et al. Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study. Clin Exp Nephrol 18:4 (2014), 662–669.
25. 25. Genovesi, S., Rossi, E., Gallieni, M., et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant 30:3 (2015), 491–498.
26. 26. Shen, J.I., Montez-Rath, M.E., Lenihan, C.R., et al. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 66:4 (2015), 677–688.
27. 27. Khalid, F., Qureshi, W., Qureshi, S., et al. Impact of restarting warfarin therapy in renal disease anticoagulated patients with gastrointestinal hemorrhage. Ren Fail 35:9 (2013), 1228–1235.
28. 28. Yodogawa, K., Mii, A., Fukui, M., et al. Warfarin use and incidence of stroke in Japanese hemodialysis patients with atrial fibrillation. Heart Vessels 31:10 (2016), 1676–1680.
29. 29. Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:9921 (2014), 955–962.
30. 30. Chan, K.E., Edelman, E.R., Wenger, J.B., et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131:11 (2015), 972–979.
31. 31. Yao, Y., Yao, J., Radparvar, M., et al. Reducing Jagged 1 and 2 levels prevents cerebral arteriovenous malformations in matrix Gla protein deficiency. Proc Natl Acad Sci U S A 110:47 (2013), 19071–19076.
32. 32. Hylek, E.M., Go, A.S., Chang, Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:11 (2003), 1019–1026.
33. 33. Morgan, C.L., McEwan, P., Tukiendorf, A., et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 124:1 (2009), 37–41.
34. 34. Limdi, N.A., Beasley, T.M., Baird, M.F., et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 20:4 (2009), 912–921.
35. 35. Sood, M.M., Rigatto, C., Bueti, J., et al. Thrice weekly warfarin administration in haemodialysis patients. Nephrol Dial Transplant 24:10 (2009), 3162–3167.
36. 36. De Vriese, A.S., Caluwé, R., Bailleul, E., et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 66:1 (2015), 91–98.
37. 37. January, C.T., Wann, L.S., Alpert, J.S., et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:21 (2014), e1–76.
38. 38. Chao, T.F., Liu, C.J., Wang, K.L., et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 11:10 (2014), 1752–1759.
39. 39. Li, J., Wang, L., Hu, J., et al. Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: a systematic review and a meta-analysis. Nutr Metab Cardiovasc Dis 25:8 (2015), 706–713.
40. 40. Liu, G., Long, M., Hu, X., et al. Effectiveness and safety of warfarin in dialysis patients with atrial fibrillation: a meta-analysis of observational studies. Medicine (Baltimore), 94(50), 2015, e2233 [1-16].
41. 41. Dahal, K., Kunwar, S., Rijal, J., et al. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest 149:4 (2016), 951–959.